

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

NATL BREAST CANCER COALITION

2. Address:

1101 17TH ST NW #1300, WASHINGTON, DC 20036

3. Principal place of business (if different from line 2):

4. Contact Name: STACEY GAGOSIAN

Telephone: 202-973-0570

E-mail (optional): sygagosian@stopbreastcancer.or

Senate ID #: 52652-12

House ID #: 34898000

7. Client Name: ☒ Self

TYPE OF REPORT

8. Year 2005 Midyear (January 1 - June 30): ☐ **OR** Year End (July 1 - December 31): ☒

9. Check if this filing amends a previously filed version of this report: ☐

10. Check if this is a Termination Report: ☐ => Termination Date: 11. No Lobbying Activity: ☐

INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000: ☐

\$10,000 or more: ☐ => Income (nearest \$20,000): _____

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000: ☐

\$10,000 or more: ☒ => Expenses (nearest \$20,000): 196,895.00

14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

☒ **Method A.** Reporting amounts using LDA definitions only

☐ **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

☐ **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

Department of Defense Peer Reviewed Breast Cancer Research program for fiscal year 2006. Meetings and calls with key congressional staff regarding program. Enactment of S.757/HR2231, the Breast Cancer and Environmental Research Act. Meetings and calls with congressional staff regarding cosponsorship and passage. Enactment of S.470, the Fair Access to Clinical Trials Act. Meetings and calls with key congressional staff regarding cosponsorship and passage. Preventing cuts to Medicaid. Conducted meetings and calls, wrote letters to Congress urging opposition to cuts. Wrote thank you notes to those who opposed the cuts.

17. House(s) of Congress and Federal agencies contacted:

Centers For Disease Control & Prevention
Centers For Medicare and Medicaid Services (CMS)
Defense, Dept of (DOD)
Food & Drug Administration (FDA)
HOUSE OF REPRESENTATIVES
Health & Human Services, Dept of (HHS)
Nat'l Institutes of Health (NIH)
President of the U.S.
SENATE
White House Office

18. Name of each individual who acted as a lobbyist in this issue area:

Name: SEXTON, SHANA

Covered Official Position (if applicable): LEGISLATIVE AND REGULATORY ASSOCIATE

Name: VISCO, FRANCES M.

Covered Official Position (if applicable): N/A

Name: YOUNGER, STACEY

Covered Official Position (if applicable): LEGISLATIVE AND POLICY ASSOCIATE

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: NATL BREAST CANCER COALITION Client Name: Self

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MED (one per page)

16. Specific lobbying issues:

Department of Defense Peer-Reviewed Breast Cancer Research Program for fiscal year 2006. Meetings and calls with key congressional staff regarding program. Enactment of S.757/HR2231, the Breast Cancer and Environmental Research Act. Meetings and calls with congressional staff regarding cosponsorship and passage. Enactment of S.470, the Fair Access to Clinical Trials Act. Meetings and calls with key congressional staff regarding cosponsorship and passage. Preventing cuts to Medicaid. Conducted meetings and calls, wrote letters to Congress urging opposition to cuts. Wrote thank you notes to those who opposed the cuts.

17. House(s) of Congress and Federal agencies contacted:

Centers For Disease Control & Prevention
Centers For Medicare and Medicaid Services (CMS)
Defense, Dept of (DOD)
Food & Drug Administration (FDA)
HOUSE OF REPRESENTATIVES
Health & Human Services, Dept of (HHS)
Nat'l Institutes of Health (NIH)
President of the U.S.
SENATE
White House Office

18. Name of each individual who acted as a lobbyist in this issue area:

Name: SEXTON, SHANA

Covered Official Position (if applicable): LEGISLATIVE AND REGULATORY ASSOCIATE

Name: VISCO, FRANCES M.

Covered Official Position (if applicable): N/A

Name: YOUNGER, STACEY

Covered Official Position (if applicable): LEGISLATIVE AND POLICY ASSOCIATE

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Signature: ON FILE Date: Feb 13, 2006

Printed Name and Title: STACEY YOUNGER GAGOSIAN - LEGISLATIVE AND REGULATORY ASSOCIATE